NGD 94-1: a specific dopamine-4-receptor antagonist.
Tallman
J F
JF
Neurogen Corporation, Branford, Connecticut 06405, USA.
D000818:Animals; D014150:Antipsychotic Agents; D001921:Brain / Q000378:metabolism*; D003024:Clozapine / Q000494:pharmacology; D018492:Dopamine Antagonists / Q000378:metabolism / Q000494:pharmacology*; D065127:Dopamine D2 Receptor Antagonists; D006801:Humans; D007093:Imidazoles / Q000378:metabolism / Q000494:pharmacology*; D011743:Pyrimidines / Q000378:metabolism / Q000494:pharmacology*; D011869:Radioligand Assay; D051381:Rats; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D050638:Receptors, Dopamine D4; D013239:Stereotyped Behavior / Q000187:drug effects; D014316:Tritium
D014150:Antipsychotic Agents; C493599:DRD4 protein, human; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; C493601:Drd4 protein, rat; D007093:Imidazoles; D011743:Pyrimidines; D017448:Receptors, Dopamine D2; D014316:Tritium; D050638:Receptors, Dopamine D4; C107692:NGD 94-1; D003024:Clozapine